Pro-Pharmaceuticals Inc.
7 Wells Avenue
Newton,
MA 02459
United States - Map
Phone: 617-559-0033
Fax: 617-928-3450
Web Site: http://www.pro-pharmaceuticals.com
| Pro-Pharmaceuticals, Inc., a development stage company, engages in the discovery and development of carbohydrate-based therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases. Its lead product candidate in development, DAVANAT, is a proprietary carbohydrate polymer comprising mannose and galactose carbohydrates, which has completed Phase II trials for the treatment of colorectal cancer in combination with 5-FU, a chemotherapy for the treatment of various types of cancer. The company has research collaborations with the Mount Sinai School of Medicine to study the anti-fibrotic effects of its carbohydrate compounds on liver fibrosis; and with Brigham and Womens Hospital to evaluate the anti-fibrotic effects of these compounds to treat acute and chronic kidney disease. Pro-Pharmaceuticals, Inc. was founded in 2000 and is based in Newton, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Theodore D. Zucconi Ph.D., 62
Chief Exec. Officer, Pres |
$
137.00K | N/A | Dr. David Platt Ph.D., 55
Consultant and Member of the Scientific Advisory Board |
$
141.00K | N/A | Dr. Eliezer Zomer Ph.D., 62
Consultant |
N/A
| N/A | Dr. Anatole A. Klyosov Ph.D., D.Sc., 62
Co-Founder, Chief Scientist and Member of the Scientific Advisory Board |
N/A
| N/A | Mr. Anthony D. Squeglia , 66
Chief Financial Officer and Principal Accounting Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.08% Nasdaq 
0.01 (3.23%) 
Profile
